Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

被引:9
|
作者
Vargas-Delgado, Ariana P. [1 ,2 ]
Arteaga Herrera, Estefania [2 ]
Tumbaco Mite, Cesar [2 ]
Delgado Cedeno, Patricia [2 ]
Van Loon, Maria Cristina [2 ]
Badimon, Juan J. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, AtheroThrombosis Res Unit, Mt Sinai Heart, One Gustave L Levy Pl, New York, NY 10029 USA
[2] Inst Ecuatoriano Corazon IECOR, Guayaquil 090513, Ecuador
关键词
sodium-glucose cotransporter type 2 inhibitors; type 2 diabetes mellitus; heart failure; ketone bodies; free fatty acids; chronic kidney disease; arterial stiffness; HEART-FAILURE; CELL-METABOLISM; EMPAGLIFLOZIN; HYDROXYLASES; OUTCOMES; DEHYDROGENASE; TRANSPORTERS; PROTECTION; DISEASE; TRIAL;
D O I
10.3390/ijms24044144
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodies and free fatty acids. The idea is that they could serve as the necessary fuel, instead of glucose, for the purposes of cardiac muscle requirements and could explain antihypertensive effects, which are independent of renal function. The adult heart, under normal conditions, consumes around 60% to 90% of the cardiac energy that is derived from the oxidation of free fatty acids. In addition, a small proportion also comes from other available substrates. In order to meet energy demands with respect to achieving adequate cardiac function, the heart is known to possess metabolic flexibility. This allows it to switch between different available substrates in order to obtain the energy molecule adenosine triphosphate (ATP), thereby rendering it highly adaptive. It must be noted that oxidative phosphorylation in aerobic organisms is the main source of ATP, which is a result of reduced cofactors. These cofactors include nicotine adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), which are the result of electron transfer and are used as the enzymatic cofactors that are involved in the respiratory chain. When there is an excessive increase in energy nutrients-such as glucose and fatty acids-which occur in the absence of a parallel increase in demand, a state of nutrient surplus (which is better known as an excess in supply) is created. The use of SGLT2i at the renal level has also been shown to generate beneficial metabolic alterations, which are obtained by reducing the glucotoxicity that is induced by glycosuria. Together with the reduction in perivisceral fat in various organs, such alterations also lead to the use of free fatty acids in the initial stages of the affected heart. Subsequently, this results in an increase in production with respect to ketoacids, which are a more available energy fuel at the cellular level. In addition, even though their mechanism is not fully understood, their vast benefits render them of incredible importance for the purposes of further research.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
    Ralph A. DeFronzo
    Luke Norton
    Muhammad Abdul-Ghani
    Nature Reviews Nephrology, 2017, 13 : 11 - 26
  • [2] Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
    DeFronzo, Ralph A.
    Norton, Luke
    Abdul-Ghani, Muhammad
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (01) : 11 - 26
  • [3] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Felice Gragnano
    Fabrizia Terracciano
    Paolo Calabrò
    Journal of Cardiovascular Translational Research, 2024, 17 : 227 - 229
  • [4] Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
    Rabizadeh, Soghra
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 17 (02)
  • [5] The effect of SGLT2 inhibitors on cardiovascular events and renal function
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    Karagiannis, Asterios
    Athyros, Vasilios G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1251 - 1261
  • [6] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Gragnano, Felice
    Terracciano, Fabrizia
    Calabro, Paolo
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (01) : 227 - 229
  • [7] Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes
    Minze, Molly G.
    Will, Kayley J.
    Terrell, Brian T.
    Black, Robin L.
    Irons, Brian K.
    CURRENT DIABETES REVIEWS, 2018, 14 (06) : 509 - 517
  • [8] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
  • [9] Cardiovascular benefit of SGLT2 inhibitors
    Mohebi, Reza
    Januzzi, James L.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2022, 59 (03) : 142 - 155
  • [10] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Abdullah Kaplan
    Emna Abidi
    Ahmed El-Yazbi
    Ali Eid
    George W. Booz
    Fouad A. Zouein
    Heart Failure Reviews, 2018, 23 : 419 - 437